Precigen (PGEN) Q2 FY26 earnings call

Precigen delivered an exceptional quarter, driven by the strong commercial momentum of PAP-SIMIUS, which propelled the company to profitability ahead of its first FDA approval anniversary. The launch continues to benefit from broad patient access, growing physician adoption across care settings, and favorable payer coverage, reinforcing confidence in its durable growth trajectory. The company is also advancing its pipeline, with updates expected for PRGN 2009 later this year.